OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Related Articles
Bexmarilimab Plus Azacitidine Meets ORR End Point in R/R Higher-Risk MDS
The addition of bexmarilimab to azacitidine elicited an ORR of 63% among patients with relapsed/refractory higher-risk myelodysplastic syndrome.
Pembrolizumab Plus Concurrent Chemoradiation Represents New SOC for High-Risk, Locally Advanced Cervical Cancer
Linda R. Duska, MD, MPH, contextualizes updated OS and PFS2 findings from the second interim analysis of KEYNOTE-A18 in locally advanced cervical cancer.
The OncFive: Top Oncology Articles for the Week of 4/27
The FDA issues a CRL to a glioma imaging agent, an sBLA seeking approval of an epcoritamab triplet in follicular lymphoma is planned for submission,…
Oncology Experts Highlight Top Takeaways From the 2025 AACR Annual Meeting
Experts from across oncology specialties shared some of the most talked-about abstracts and discussions from the 2025 AACR Annual Meeting.
Personalized Therapy, Surgical Staging, and Expanded Screening Guidelines Drive Progress in NSCLC
Isabel Preeshagul, DO, MBS, discusses the need for a nuanced approach when selecting between targeted therapies in ALK- and EGFR-altered NSCLC.
FDA Grants Fast Track Designation to Emactuzumab for Unresectable TGCT
The FDA granted fast track designation to emactuzumab for unresectable tenosynovial giant cell tumor.
Novel Adjuvant Strategies Reshape HER2+ Breast Cancer Treatment
Paolo Tarantino, MD, discusses adjuvant strategies, trial data, and risk stratification shaping HER2+ breast cancer care.
Biomarker Research Aims to Overcome Treatment Challenges in Squamous Cell Carcinoma of the Lung
Fawzi F Abu Rous, MD, discusses ongoing efforts to address unmet needs in the management of squamous cell carcinoma of the lung.
ADCs Are Poised to Transform the Metastatic TNBC Treatment Arsenal
Nerea Lopetegui-Lia, MD, discusses ongoing trials investigating ADCs that are shaking up the metastatic triple-negative breast cancer setting.
Cyclin E1 Positivity May Enhance Patient Selection for Azenosertib in Platinum-Resistant Ovarian Cancer
Fiona Simpkins, MD, discusses the use of cyclin E1 positivity as a biomarker of azenosertib response in platinum-resistant ovarian cancer.